Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-Nitro-L-Arginine methyl ester-induced hypertension and vascular senescence

Amanda E. Boe, Mesut Eren, Sheila B. Murphy, Christine E. Kamide, Atsuhiko Ichimura, David Terry, Danielle McAnally, Layton H. Smith, Toshio Miyata, Douglas E. Vaughan

Research output: Contribution to journalArticlepeer-review

94 Citations (Scopus)


BACKGROUND - : Long-term inhibition of nitric oxide synthase by L-arginine analogues such as N-nitro-L-arginine methyl ester (L-NAME) has been shown to induce senescence in vitro and systemic hypertension and arteriosclerosis in vivo. We previously reported that plasminogen activator inhibitor-1 (PAI-1)-deficient mice (PAI-1) are protected against L-NAME-induced pathologies. In this study, we investigated whether a novel, orally active PAI-1 antagonist (TM5441) has a similar protective effect against L-NAME treatment. Additionally, we studied whether L-NAME can induce vascular senescence in vivo and investigated the role of PAI-1 in this process. METHODS AND RESULTS - : Wild-type mice received either L-NAME or L-NAME and TM5441 for 8 weeks. Systolic blood pressure was measured every 2 weeks. We found that TM5441 attenuated the development of hypertension and cardiac hypertrophy compared with animals that had received L-NAME alone. Additionally, TM5441-treated mice had a 34% reduction in periaortic fibrosis relative to animals on L-NAME alone. Finally, we investigated the development of vascular senescence by measuring p16 expression and telomere length in aortic tissue. We found that L-NAME increased p16 expression levels and decreased telomere length, both of which were prevented with TM5441 cotreatment. CONCLUSIONS - : Pharmacological inhibition of PAI-1 is protective against the development of hypertension, cardiac hypertrophy, and periaortic fibrosis in mice treated with L-NAME. Furthermore, PAI-1 inhibition attenuates the arterial expression of p16 and maintains telomere length. PAI-1 appears to play a pivotal role in vascular senescence, and these findings suggest that PAI-1 antagonists may provide a novel approach in preventing vascular aging and hypertension.

Original languageEnglish
Pages (from-to)2318-2324
Number of pages7
Issue number21
Publication statusPublished - 2013 Nov 19


  • Aging
  • Hypertension
  • Nitric oxide synthase


Dive into the research topics of 'Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-Nitro-L-Arginine methyl ester-induced hypertension and vascular senescence'. Together they form a unique fingerprint.

Cite this